皮肤科药物未知不良反应:丹麦真实世界数据无假设筛查研究
该研究基于丹麦全国健康登记数据,对1996至2022年间5,877,711名使用皮肤科药物或相关免疫抑制剂的居民进行无假设筛查,采用序列对称分析(SSA)评估药物-药物及药物-诊断配对信号。结论认为SSA可有效补充传统药物警戒。
要点
- SSA筛查可识别皮肤科药物潜在未知不良反应信号。
- 异维A酸与全身性糖皮质激素及痔疮治疗存在信号。
- 氯倍他索与房颤/房扑信号需进一步 causality 研究。
核心结论
- 基于丹麦全国真实世界数据的无假设SSA筛查能有效识别皮肤科药物潜在未知不良反应信号。
研究设计与样本
- 全国性、登记库为基础、无假设筛查研究,纳入1996至2022年5,877,711名丹麦居民,数据分析于1995至2024年。
主要发现
- 异维A酸与全身性糖皮质激素调整SR 1.44(95%CI 1.35-1.53),CCO OR 1.78(95%CI 1.61-1.98)。
- 异维A酸与痔疮治疗调整SR 1.58(95%CI 1.49-1.68),CCO OR 1.83(95%CI 1.68-1.98)。
- 硫唑嘌呤与骨修饰药物调整SR 1.42(95%CI 1.33-1.53),CCO OR 1.57(95%CI 1.36-1.81)。
- 特比萘芬与降脂治疗调整SR 1.04(95%CI 1.01-1.08),CCO OR 1.14(95%CI 1.07-1.20);与维生素B12/叶酸使用调整SR 1.20(95%CI 1.14-1.26),CCO OR 1.12(95%CI 1.02-1.22)。
临床怎么用
- 临床药师可关注SSA筛出的信号,对相关药物组合或诊断保持警惕。
- 对异维A酸、硫唑嘌呤、特比萘芬、氯倍他索的可疑关联,建议结合患者具体情况评估。
局限性
- 研究聚焦于识别关键信号以供后续专项研究,并非对所有潜在关联的穷尽分析。
- 信号需进一步靶向研究以支持因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many adverse drug reactions (ADRs) to dermatological drugs may be underrecognized due to limitations in traditional surveillance. Systematic, hypothesis-free screening for such ADRs using real-world data is an underutilized approach in dermatology. OBJECTIVE: The aim was to systematically screen commonly used dermatological drugs for potential unknown ADR signals using nationwide Danish health register data and to evaluate sequence symmetry analysis (SSA) as an epidemiological screening method in pharmacovigilance. This evaluation focuses on identifying key signals for dedicated follow-up studies, not on an exhaustive analysis of all potential associations. METHODS: A nationwide, register-based, hypothesis-free screening study using Danish national health registers was conducted. The study cohort comprised 5,877,711 Danish residents prescribed dermatological drugs or relevant immunosuppressants linked to a dermatological indication between 1996 and 2022. Data were analyzed from 1995 to 2024. Exposures were the first dispensation of included dermatological drugs. The primary outcome measure was the trend-adjusted sequence ratio (SR), an estimate of the incidence rate ratio for rare events, with 95% confidence intervals (CIs), for incident drug-drug and drug-diagnosis pairs within ±12-month windows of exposure initiation. To assess directionality, supplementary case-crossover (CCO) analyses were performed on top-ranked signals, estimating odds ratios (ORs) with 95% CIs. RESULTS: The screening of 22.5 million incident exposure prescriptions yielded 4010 drug-drug and 22,234 drug-diagnosis pairs. After filtering and review, several potential unknown ADR signals were identified and prioritized. Signals were manually reviewed and categorized by clinical experts to identify plausible novel ADRs. Notable associations (adjusted SR [95% CI]; CCO OR [95% CI]) included isotretinoin with systemic corticosteroids (1.44 [1.35-1.53]; 1.78 [1.61-1.98]) and hemorrhoid treatments (1.58 [1.49-1.68]; 1.83 [1.68-1.98]); azathioprine with bone-modifying drugs (1.42 [1.33-1.53]; 1.57 [1.36-1.81]); terbinafine with lipid-lowering therapy (1.04 [1.01-1.08]; 1.14 [1.07-1.20]) and vitamin B12/folate use (1.20 [1.14-1.26]; 1.12 [1.02-1.22]); and clobetasol with atrial fibrillation/flutter (1.11 [1.06-1.17]; 1.07 [1.00-1.14]). CONCLUSIONS: Systematic hypothesis-free screening using SSA on nationwide real-world data can effectively identify potential unknown ADRs for dermatological drugs. The specific signals found in this study potentially have clinical implications and warrant further targeted investigations to support causality. This approach supports the implementation of routine real-world data screening to supplement traditional pharmacovigilance.
引用
- Delvin T, Bygum A, Lund LC, et al. Unsuspected Adverse Drug Reactions to Dermatologic Medications: An Epidemiological Hypothesis-Free Screening Study of Real-World Data in Denmark. Drug Saf. 2025. PMID: 41348382. doi:10.1007/s40264-025-01639-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。